Rare Community Profiles: Revving for Hope: Raising HoFH Awareness in One Ride
source: pixabay.com

Rare Community Profiles: Revving for Hope: Raising HoFH Awareness in One Ride

  Rare Community Profiles is a Patient Worthy article series of long-form interviews featuring various stakeholders in the rare disease community, such as patients, their families, advocates, scientists, and more.…

Continue Reading Rare Community Profiles: Revving for Hope: Raising HoFH Awareness in One Ride
Study: Detection of Lysosomal Acid Lipase Deficiency in Japan FH Patients
source: shutterstock.com

Study: Detection of Lysosomal Acid Lipase Deficiency in Japan FH Patients

In a study published in the scientific journal Atherosclerosis, a team of researchers sought to screen patients in Japan who had abnormally high LDL cholesterol (LDL-C) and a suspected diagnosis of familial…

Continue Reading Study: Detection of Lysosomal Acid Lipase Deficiency in Japan FH Patients

VERVE-101 Shows Promise in Treating HeFH, Phase 1b Study Results Show

Heterozygous familial hypercholesterolemia (HeFH) can be difficult to control on available standard-of-care cholesterol-lowering medications. Therapeutic interventions are needed to reduce high LDL cholesterol levels and improve health and quality-of-life for…

Continue Reading VERVE-101 Shows Promise in Treating HeFH, Phase 1b Study Results Show
September 24 is FH Awareness Day!
Xanthoma is an easy sign of high cholesterol conditions like HeFH. If you see this, please go to the doctor immediately! Source: Wikipedia

September 24 is FH Awareness Day!

An estimated 1.3 million people across the United States, and 30 million people globally, live with familial hypercholesterolemia (FH). This rare inherited form of high low-density lipoprotein (LDL) cholesterol remains…

Continue Reading September 24 is FH Awareness Day!
These Clinical Trials Could be Game Changers in the Latter Half of 2023
source: shutterstock.com

These Clinical Trials Could be Game Changers in the Latter Half of 2023

In a story from BioPharma Dive, a number of high-profile clinical trials are under way that could see conclusive results by the end of 2023. While some of these are…

Continue Reading These Clinical Trials Could be Game Changers in the Latter Half of 2023
Adding Evinacumab to Care Plan Can Significantly Increase HoFH Life Expectancy
https://pixabay.com/en/doctor-blood-life-veins-pain-2346235/

Adding Evinacumab to Care Plan Can Significantly Increase HoFH Life Expectancy

In the average person, you would expect to see normal to near-optimal low-density lipoprotein (LDL) cholesterol levels sitting at 129 mg/DL or lower; levels under 100 are seen as healthier.…

Continue Reading Adding Evinacumab to Care Plan Can Significantly Increase HoFH Life Expectancy
“For Seven Years I Thought I had a Perfectly Healthy Child” – Jessica’s Story
source: unsplash.com

“For Seven Years I Thought I had a Perfectly Healthy Child” – Jessica’s Story

This story was originally published by the Family Heart Foundation, a Patient Worthy partner organization. When Jessica’s father died of a heart attack at the young age of 54, she…

Continue Reading “For Seven Years I Thought I had a Perfectly Healthy Child” – Jessica’s Story
September 24 is Familial Hypercholesterolemia Awareness Day
source: pixabay.com

September 24 is Familial Hypercholesterolemia Awareness Day

September 24, 2022 will be recognized as Familial Hypercholesterolemia (FH) Awareness Day, a time to spread awareness about this under-recognized condition among the general public and in the medical field.…

Continue Reading September 24 is Familial Hypercholesterolemia Awareness Day
The FDA has Announced Their Approval of Evkeeza for Homozygous Familial Hypercholesterolemia
source: pixabay.com

The FDA has Announced Their Approval of Evkeeza for Homozygous Familial Hypercholesterolemia

The FDA has just announced their approval of Evkeeza as a therapy for those living with homozygous familial hypercholesterolemia. The therapy is owned by Regeneron Pharmaceuticals. It was evaluated with…

Continue Reading The FDA has Announced Their Approval of Evkeeza for Homozygous Familial Hypercholesterolemia
Study: Familial Hypercholesterolemia is Diagnosed Late and Under-treated in US Children
source: pixabay.com

Study: Familial Hypercholesterolemia is Diagnosed Late and Under-treated in US Children

According to an announcement from the FH Foundation, data from the FH Foundation’s CASCADE FH Registry, published in The Journal of Pediatrics, has determined that children living with familial hypercholesterolemia regularly…

Continue Reading Study: Familial Hypercholesterolemia is Diagnosed Late and Under-treated in US Children
Heterozygous Familial Hypercholesterolemia Trial Shows Positive Results of Therapy in Teenagers
source: pixabay.com

Heterozygous Familial Hypercholesterolemia Trial Shows Positive Results of Therapy in Teenagers

Researchers in Canada have just released positive results from their heterozygous familial hypercholesterolemia (HeFH) clinical trial. This investigation was examining the effect of Repatha on teenagers with the condition. The trial…

Continue Reading Heterozygous Familial Hypercholesterolemia Trial Shows Positive Results of Therapy in Teenagers
ICYMI: Good Results From Evinacumab for Rare Form of Familial Hypercholesterolemia
source: pixabay.com

ICYMI: Good Results From Evinacumab for Rare Form of Familial Hypercholesterolemia

  A press release issued recently by Regeneron Pharmaceuticals heralded the acceptance of a Biologics License Application by the FDA for Priority Review of its investigational drug, evinacumab. The Priority…

Continue Reading ICYMI: Good Results From Evinacumab for Rare Form of Familial Hypercholesterolemia
BLA for Evinacumab, a Treatment for HoFH, Receives Priority Review Status
source: pixabay.com

BLA for Evinacumab, a Treatment for HoFH, Receives Priority Review Status

  This week, Regeneron Pharmaceuticals announced that their Biologics License Application (BLA) for evanicumab, a treatment for homozygous familial hypercholesterolemia (HoFH), was granted Priority Review status by the FDA. The…

Continue Reading BLA for Evinacumab, a Treatment for HoFH, Receives Priority Review Status
Machine Learning Found to be a Better Diagnostic Tool than Dutch Lipid Score for Familial Hypercholesterolemia
source: pixabay.com

Machine Learning Found to be a Better Diagnostic Tool than Dutch Lipid Score for Familial Hypercholesterolemia

Ana Pina from the Centro de Estudos de Doencas Cronicas at NOVA Medical School in Portugal, and her colleagues recently published an innovative study regarding the diagnosis of familial hypercholesterolemia (FH).…

Continue Reading Machine Learning Found to be a Better Diagnostic Tool than Dutch Lipid Score for Familial Hypercholesterolemia
Faulty Proteins and Failed Genes: Understanding the Biology Behind Congenital Diseases
source: pixabay.com

Faulty Proteins and Failed Genes: Understanding the Biology Behind Congenital Diseases

Patients with congenital diseases often experience a range of uncomfortable symptoms. On one side of the world, a family with erythromelalgia, a painful condition which can cause redness and swelling…

Continue Reading Faulty Proteins and Failed Genes: Understanding the Biology Behind Congenital Diseases